Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ERErnexa Therapeutics Inc. logo

Ernexa Therapeutics Inc. (ERNA)

NASDAQ Global Market · Currency in USD
$2.07 ▼ -0.01 (-0.48%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.26 ▲ +0.20 (+9.44%)
After hours: Oct 23, 7:50 PM ET

Summary

Previous Close
$2.08
Open
$2.09
Day's Range
$2.01 – $2.13
52 Week Range
$1.84 – $71.50
Volume
5,674
Avg. Volume
351,882
Market Cap
$3.37M
Beta (5Y Monthly)
2.65
PE Ratio (TTM)
--
EPS (TTM)
-$10.36
Earnings Date
Nov 6, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Ernexa Therapeutics Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
5
CEO
Sanjeev Luther

Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer.

Earnings

Next report: Fri, Nov 6, 2026
EPS estimate -$3.84
DateEst.Actual
Aug 6, 2026-$3.30-$3.40Miss
May 11, 2026-$1.95-$6.95Miss
Mar 13, 2026–-$0.25
Nov 7, 2025-$33.00-$0.15Beat
Aug 13, 2025-$39.00-$0.61Beat
May 7, 2025-$48.00-$2.25Beat

Get free alerts on ERNA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.